Clinical Trials Incentive Program (Israel Innovation Authority) — Historical Reference

Clinical Trials Incentive Program (Israel Innovation Authority) — Historical Reference

This page is a historical reference, not an open funding call. The Israel Innovation Authority’s current English programme index is live, but it does not list a programme called the Clinical Trials Incentive Program. The Authority’s current calls archive also lists other health, pilot, research, and international-collaboration calls without announcing a new round under this name. No current application window, award amount, or successor call for this exact programme name was found on the official pages reviewed.

The deadline in the metadata is the closed date retained for the archived record: 2025-03-24. It is not a live invitation to submit. The historicalReference = true flag is intentional: it lets the page preserve useful programme history while preventing the expired date from being presented as a current opportunity.

What the official-source check established

The verified current destination is the Israel Innovation Authority’s English programmes index:

https://innovationisrael.org.il/en/programs/

That index identifies the Authority’s active programme catalogue and groups programmes by division and collaboration type. It includes the R&D Fund, the Pilots Fund, international collaboration mechanisms, startup support, and technological-infrastructure programmes. The Clinical Trials Incentive Program is not among the named entries on that live index.

The Authority also maintains a calls-for-proposals archive:

https://innovationisrael.org.il/en/calls_for_proposal/

That archive is the relevant place to check for a dated submission window. Its current health-related entries are separate calls with their own names, dates, scope, and application rules. A health or medical-technology call appearing in the archive should not be treated as a replacement for this page unless the Authority explicitly says that it is the successor. A programme catalogue entry and a dated call are different things: the former explains a standing mechanism, while the latter controls who can apply, what work is accepted, what costs qualify, and when a submission closes.

The former programme URL was:

https://innovationisrael.org.il/en/program/clinical-trials-incentive-program

That address is no longer a usable current application route. The live programmes index is therefore retained as the official URL metadata for this archive entry. It is a source-navigation page, not evidence that the historical programme has reopened.

What this record used to describe

The archived listing concerned Israeli life-sciences companies seeking public support for clinical-trial activity involving innovative medical technologies or therapeutics. Its subject was later-stage work than a simple idea-validation grant: a company would need a defined product or therapy, a clinical question, a plan for generating patient or clinical evidence, and a credible route through the relevant regulatory and operational steps.

Those broad characteristics remain a useful description of the type of applicant the old record was intended to reach. They are not current eligibility rules. The Authority has not published a current call under this exact name that confirms company size, incorporation requirements, trial location, technology readiness, eligible expenses, matching funds, reporting duties, or the treatment of clinical research organizations. A company should not rely on the old record as proof that any of those conditions still apply.

The old listing also carried a grant range of 30% to 50% of approved clinical-trial costs. That amount is withdrawn from this page. The current Authority pages reviewed do not state that range for a Clinical Trials Incentive Program, and current support rates vary by programme and call. A rate shown for another health-tech, pilot, or R&D mechanism cannot be transferred to this historical entry.

Who should use this archive entry

This page may help an Israeli medical-technology, digital-health, biotechnology, or therapeutics company understand why an older funding reference no longer provides an application route. It is also useful when reviewing an old budget, board memo, investor document, or clinical-development plan that cites the Clinical Trials Incentive Program. In that situation, treat the programme name and the retained closing date as historical identifiers, then replace every funding assumption with terms from a current official call.

It is not a current route for:

• a company looking for a new clinical-trial grant;
• a hospital or investigator seeking research funding;
• a medical-device team seeking confirmation of regulatory or reimbursement support;
• a startup preparing a budget around the former 30% to 50% figure; or
• an applicant trying to submit through the old programme URL.

The right next step is to classify the work before choosing a current Authority mechanism. A product that needs technical R&D may belong under the R&D Fund. A product ready for real-world testing may fit a pilot mechanism. A project built with a foreign hospital or company may need an international collaboration call. A project facing a defined regulatory barrier may fit a regulatory pilot call. These are possible routes, not confirmed successors, and the live call document controls the answer.

How to find a current fit

Start at the official programmes index and read the descriptions of the R&D Fund, Pilots Fund, and international collaboration programmes. Then move to the calls-for-proposals archive and search for the current health, medical-device, biotechnology, digital-health, or clinical-environment calls. Read the full page and its attachments, not only the search-result summary. The Authority’s pages frequently separate the standing programme description from the dated call that supplies the practical requirements.

For each candidate call, record the exact programme name, the issuing division, the call opening and closing dates, the eligible applicant type, the technology or sector scope, the maximum approved budget, the support rate, the permitted project period, and the submission system. Do not combine the deadline from one call with the rate or eligibility rules from another. This is especially important in health technology, where a pilot in a hospital, clinical evidence generation, product development, and regulatory testing may be funded through different mechanisms even when the same company is involved.

If no call matches, contact the Authority through its current contact route and describe the project in operational terms: company registration and location, product stage, clinical activity, intended sites, regulatory status, requested work, and the type of support sought. Ask whether a current programme or planned call covers the work. Keep the response with the project file. A written answer from the Authority is stronger evidence than assuming that a similar title means the old mechanism was renamed.

Preparation for a future clinical-support application

Although this entry is closed, the preparation work below remains relevant if the Authority announces a new clinical or health-tech call. It should be adapted to the new call rather than copied as if it were a current checklist.

Define the clinical evidence question

State the patient or user problem, the product or intervention, the comparator or existing workflow, and the endpoint that will show whether the project worked. Explain whether the planned activity is a feasibility study, pilot, validation study, pivotal trial, or another form of clinical evidence. A reviewer should be able to tell what will be learned, who will be responsible, and how the result affects the next development decision.

Separate trial costs from general company costs

Build a budget that identifies personnel, sites, monitoring, data management, statistical work, manufacturing or study supplies, regulatory preparation, insurance, and other requested items. Mark which costs are directly tied to the proposed work and which are company overhead. Do not assume that every cost associated with a clinical programme is eligible. The current call should define the accepted cost categories, accounting evidence, procurement rules, and any requirement for matching resources.

Show readiness and approvals

Describe the product version that will be used, the evidence already available, the remaining technical risks, and the regulatory path. Identify the ethics committee or institutional review process that applies, the proposed sites, the principal investigator, data-protection responsibilities, and the safety-reporting plan. If an approval has not yet been obtained, give the expected sequence and owner rather than implying that the study can start immediately.

Make recruitment arithmetic visible

Support the recruitment plan with the number of sites, eligible population, expected screening rate, enrolment rate, retention assumption, and contingency if recruitment is slower than expected. Explain how the endpoint and sample size were chosen. For a device or digital-health product, include the workflow, training, technical support, data-quality checks, and method for handling device failure or missing observations.

Name the delivery team

List the company lead, clinical lead, statistician or data lead, regulatory owner, finance owner, and site contacts. State what each person will deliver and what outside partners will provide. A hospital letter should identify the department, investigator, site role, and expected commitment. A generic expression of interest is not a substitute for a defined site plan.

Plan reporting and closeout

Include milestones for approvals, site activation, first participant or first use, interim review, database lock or equivalent evidence freeze, analysis, and final reporting. Define who will keep source records, reconcile invoices, manage protocol changes, report safety events, and preserve the data needed for an audit. The Authority’s future call may impose different milestones, but the project should be operationally ready to map onto them.

Funding and eligibility: what not to assume

There is no current amount to quote for this page. Do not use the former 30% to 50% figure in a financial model, and do not infer a new ceiling from a different Authority programme. Likewise, do not assume that an Israeli company automatically qualifies because its product is medical or because it has already received another form of public support. A new call may limit applicants by company status, development stage, ownership, project location, technology category, clinical partner, or prior funding.

The same caution applies to clinical-trial expenses. Some calls may fund development and pilot work but exclude routine care, ordinary commercial deployment, previously incurred costs, or activities that do not add technological R&D. Others may require a named public-sector partner, a foreign partner, a regulatory authority, or a specific testing environment. The call document, guidelines, and application system are the controlling sources for those details.

Status and monitoring guidance

The programme is closed as an identifiable current call, and no next round under this name is announced on the official pages reviewed for this update. The page should remain marked as a historical reference until the Authority publishes a clear new call or successor notice. If that happens, the replacement update should verify the new title, official URL, deadline, funding terms, eligible applicants, required attachments, and online submission route before changing this entry back into a live opportunity.

For now, readers should use the official Authority pages below as the source of truth. Check the programme index for current mechanisms, the calls archive for dated windows, and the specific call page for the terms that govern an application. Do not submit through the retired programme URL, and do not treat this archive entry’s date or former funding range as a current offer.

Official references

• Israel Innovation Authority programmes index
• Israel Innovation Authority calls-for-proposals archive
• International Health-Tech Program – Phase I, a separate historical health-tech call with its own terms
• Regulatory Sandbox for Breakthrough AI Technologies in Healthcare, a separate healthcare pilot call with its own terms
• Israel Innovation Authority contact page

The official pages confirm the current catalogue and the existence of separately governed health-related calls. They do not announce a new Clinical Trials Incentive Program cycle. This entry therefore preserves the historical record, removes unsupported current-cycle claims, and directs applicants to verify a live Authority call before preparing a submission.